Overview

Evaluation of Pharmacokinetics and Safety of A006 in Healthy Volunteers

Status:
Completed
Trial end date:
2015-03-01
Target enrollment:
Participant gender:
Summary
The objective of this study is to evaluate the pharmacokinetics (PK) and safety profiles of A006, an Albuterol dry powder inhaler (DPI), following a single dose of 110 mcg (T1) or 220 mcg (T2), in healthy male and female adult volunteers.
Phase:
Phase 2
Details
Lead Sponsor:
Amphastar Pharmaceuticals, Inc.
Treatments:
Albuterol